Galectin Therapeutics Inc stock is traded at $3.05, with a volume of 181,587. It is down -2.87% in the last 24 hours and down -17.34% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Previous Close:
$3.14
Open:
$3.16
24h Volume:
181,587
Relative Volume:
0.92
Market Cap:
$307.59M
Revenue:
-
Net Income/Loss:
-$26.25M
P/E Ratio:
-
EPS:
-$0.4099
Net Cash Flow:
-$20.05M
1W Performance:
-2.87%
1M Performance:
-17.34%
6M Performance:
+36.77%
1Y Performance:
-44.85%
1-Day Range:
$2.93$3.31
1-Week Range:
$2.93$3.53
52-Week Range:
$2.03$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
678-620-3186Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS